Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

June 12, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, today announced that SER-109 (Firmacute Eubacterial Spores, Purified Suspension, Encapsulated), its lead product candidate under investigation for the prevention of recurrent Clostridium difficile infection (CDI) in adults, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA).

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

June 12, 2015

 - In lower risk myelodysplastic syndromes patients, longer-term treatment with luspatercept led to sustained increases in hemoglobin levels and transfusion independence -

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

June 12, 2015

 - Potential for combined Manocept and Accurin platforms to target the tumor microenvironment -

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

June 12, 2015

 IDH2-Mutant Inhibitor Shows Durable Responses of More than 15 Months in Patients with Advanced Acute Myeloid Leukemia (AML) and Other Blood Cancers

Proof-of-Concept Demonstrated in Myelodysplastic Syndrome (MDS) and Untreated AML

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

June 12, 2015

 IDH1-Mutant Inhibitor Shows Durable Responses of Up to 11 Months in Patients with Advanced Acute Myeloid Leukemia (AML) and Other Blood Cancers

Three Expansion Cohorts and Global Registration-Enabling Program Remain on Track

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

June 12, 2015

 Data Support Activation of DRIVE PK, a Global Phase 2 Study of AG-348 in PK Deficiency Patients

First Data from Natural History Study of PK Deficiency Characterize Severity of this Rare Genetic Disease

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

June 10, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-120 for treatment of patients with acute myelogenous leukemia (AML). AG-120 is an oral, first-in-class IDH1 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH1 mutation.

Flagship Ventures Welcomes 16 VentureLabs® Fellows Commencing Its Seventh Annual Fellowship Program

Flagship Ventures Welcomes 16 VentureLabs® Fellows Commencing Its Seventh Annual Fellowship Program

June 10, 2015

Program Expands to Accelerate Venture Creation

CAMBRIDGE, Mass., June 10, 2015 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced the start of its seventh VentureLabs® Fellowship Program, a rare opportunity for graduate and post-graduate students to experience VentureLabs' unique approach to innovation, company creation, and entrepreneuring.

Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout

Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout

June 10, 2015

The first immunotherapeutic candidate from Selecta's proprietary Synthetic Vaccine Particle (SVP) Platform, SEL-212 aims at addressing the high unmet needs of refractory and tophaceous gout patients

Selecta's SVP immunotherapeutic platform has broad applications, including inhibition of immunogenicity for biologic therapies and antigen-specific treatment of allergies and autoimmune diseases

Pronutria Biosciences Announces Key Additions to Executive Team

Pronutria Biosciences Announces Key Additions to Executive Team

June 2, 2015

Anders Gram, Ph.D., appointed Chief Production and Global Supply Chain Officer and Larry Bell, M.D., appointed Global Head of Regulatory Affairs and Pharmacovigilance